HC Wainwright Has Negative Forecast for ARQT Q1 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Equities research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Arcutis Biotherapeutics in a note issued to investors on Thursday, February 26th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.08) for the quarter, down from their previous forecast of ($0.02). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ FY2026 earnings at $0.18 EPS, FY2027 earnings at $0.83 EPS, FY2028 earnings at $1.45 EPS and FY2029 earnings at $1.91 EPS.

Other equities analysts also recently issued reports about the company. Mizuho decreased their target price on Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research note on Monday. Needham & Company LLC raised their price target on Arcutis Biotherapeutics from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Zacks Research downgraded Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 29th. TD Cowen increased their target price on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Wall Street Zen cut Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.86.

Arcutis Biotherapeutics Trading Down 8.2%

NASDAQ ARQT opened at $24.76 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.99 and a current ratio of 3.17. Arcutis Biotherapeutics has a one year low of $11.86 and a one year high of $31.77. The company has a 50-day simple moving average of $27.13 and a 200-day simple moving average of $23.98. The firm has a market capitalization of $3.07 billion, a PE ratio of -176.84 and a beta of 1.70.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.10. Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. The company had revenue of $129.50 million for the quarter, compared to analysts’ expectations of $110.79 million.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Focus Partners Wealth lifted its position in Arcutis Biotherapeutics by 0.8% in the third quarter. Focus Partners Wealth now owns 65,196 shares of the company’s stock worth $1,237,000 after purchasing an additional 490 shares during the period. Arizona State Retirement System lifted its holdings in shares of Arcutis Biotherapeutics by 1.8% in the third quarter. Arizona State Retirement System now owns 31,685 shares of the company’s stock valued at $597,000 after buying an additional 568 shares during the period. Schroder Investment Management Group lifted its holdings in shares of Arcutis Biotherapeutics by 1.1% in the fourth quarter. Schroder Investment Management Group now owns 57,136 shares of the company’s stock valued at $1,604,000 after buying an additional 594 shares during the period. AlphaQuest LLC boosted its stake in Arcutis Biotherapeutics by 5.7% during the third quarter. AlphaQuest LLC now owns 12,603 shares of the company’s stock valued at $238,000 after buying an additional 682 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Arcutis Biotherapeutics by 124.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after acquiring an additional 698 shares during the period.

Insider Buying and Selling at Arcutis Biotherapeutics

In related news, insider Patrick Burnett sold 9,794 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $25.81, for a total value of $252,783.14. Following the completion of the sale, the insider owned 80,651 shares of the company’s stock, valued at $2,081,602.31. This represents a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Larry Todd Edwards sold 2,052 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $25.50, for a total transaction of $52,326.00. Following the completion of the transaction, the insider owned 148,865 shares of the company’s stock, valued at $3,796,057.50. This represents a 1.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 112,999 shares of company stock valued at $2,960,174. 9.40% of the stock is currently owned by insiders.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.